AzTrials
AzTrials

GlioblastomaPhysMRRTNCT05970757

Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma

A study testing Extended MRI in people with Glioblastoma, run by Erasmus Medical Center at 1 site in Netherlands.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells remaining after surgery. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Glioblastoma
What is being tested?
Extended MRI
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteNetherlands
Study dates
14 Jul 2022to 15 Dec 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed consent;
  • Adults (18 years or older);
  • diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy;
  • referred to outpatient clinic of the Department of Radiotherapy to undergo standard treatment with high-dose RT.
  • Patients eligible for 30x2Gy or 15x2.67Gy

Who cannot join

  • Contraindication for MRI
  • Contraindication for use of gadolinium-based contrast agent (i.e. subject having renal deficiency)
  • Unable to give informed consent

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Erasmus Medical Center

    Rotterdam, South Holland, 3015GD

Other trials in Netherlands

About this study

After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells remaining after surgery. Currently, the GTV is delineated on conventional imaging techniques that are only visualizing macroscale structural changes due to the presence of a large number of tumour cells. After delineating these visible macroscale changes, the GTV is expanded in all directions with 1.5cm into visibly healthy tissue to account for microscale tumour invasion. This standard CTV therefore also contains healthy tissue that should not be receiving radiation, causing side effects of treatment, hereby reducing quality of life for patients.

Generating a physiological CTV, in which microscale invasion of tumour cells is taken into account specifically whilst sparing healthy tissue that is not in need of radiation, is essential for reducing side effects of radiotherapy. To do so, visualisation is necessary of physiological processes of tumour cells, which are present before macroscale structural changes occur. State-of-the-art MRI techniques are now in use at the Erasmus MC that can assess these physiological processes, including oxygenation status and cell proliferation.

We aim to generate proof-of-concept of using a physiological CTV for radiotherapy treatment planning for patients with brain tumours. By extending the clinical standard MRI session used for radiotherapy planning in 10 patients diagnosed with glioblastoma with advanced MRI techniques that assess oxygenation status and cell proliferation, we will generate the physiological CTV including this information and illustrate that it is more precise in capturing microscale tumour invasion. This proof-of-principle work will be used to obtain external funding to perform the much needed, and the first of its kind globally, clinical trial to show the benefit of a physiological CTV for radiotherapy treatment planning in glioblastoma.

Read the detailed description

Introduction: After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells remaining after surgery. Currently, the GTV is delineated on conventional imaging techniques that are only visualizing macroscale structural changes due to the presence of a large number of tumour cells. After delineating these visible macroscale changes, the GTV is expanded in all directions with 1.5cm into visibly healthy tissue to account for microscale tumour invasion. This standard CTV therefore also contains healthy tissue that should not be receiving radiation, causing side effects of treatment, hereby reducing quality of life for patients.

Generating a physiological CTV, in which microscale invasion of tumour cells is taken into account specifically whilst sparing healthy tissue that is not in need of radiation, is essential for reducing side effects of radiotherapy. To do so, visualisation is necessary of physiological processes of tumour cells, which are present before macroscale structural changes occur. State-of-the-art MRI techniques are now in use at the Erasmus MC that can assess these physiological processes, including oxygenation status and cell proliferation.

We aim to generate proof-of-concept of using a physiological CTV for radiotherapy treatment planning for patients with brain tumours. By extending the clinical standard MRI session used for radiotherapy planning in 10 patients diagnosed with glioblastoma with advanced MRI techniques that assess oxygenation status and cell proliferation, we will generate the physiological CTV including this information and illustrate that it is more precise in capturing microscale tumour invasion. This proof-of-principle work will be used to obtain external funding to perform the much needed, and the first of its kind globally, clinical trial to show the benefit of a physiological CTV for radiotherapy treatment planning in glioblastoma.

Rationale: Current treatment management of patients with IDH-wildtype glioblastoma is sub-optimal because of two main issues: (1) Creating an accurate target volume for radiotherapy, a key aspect of glioblastoma treatment, containing all remaining tumour cells after surgery that is impossible with the conventional CT and MRI imaging techniques currently used and (2) in the follow-up of patients after radiotherapy, conventional MRI is incapable of distinguishing tumour progression from treatment effects. The solution to these issues lies in accurate and non-invasive assessment of physiological processes of tumour cells to enable delineation of the true physiological clinical target volume (CTV) for radiotherapy planning and to allow for early detection of true tumour progression during treatment follow-up.

Objective: Generate proof-of-concept of using a physiological CTV for radiotherapy treatment planning for patients with brain tumours.

Study design: By extending the clinical standard MRI session used for radiotherapy planning in patients diagnosed with glioblastoma with advanced MRI techniques that assess oxygenation status and cell proliferation, a physiological CTV will be generated for each patient in addition to the standard CTV. Treatment for each patient will be according to the current standard in which the standard CTV is used. Initial analysis will include comparing both CTVs in terms of volume and location. Patient follow-up will occur according to the clinical standard, including the standard MRI scan protocols, for a maximum of 2 years. Pattern-of-failure analysis will be done to compare the standard CTV and physiological CTV. It is hypothesized that the physiological CTV will be smaller than the standard CTV, whilst having the same pattern-of-failure.

Study population: 10 patients (> 18 years), diagnosed with IDH-wildtype glioblastoma, as confirmed by molecular or immunohistochemistry analysis post resection/biopsy and referred to outpatient clinic of the department of Radiotherapy to undergo standard treatment with radiotherapy.

Intervention (if applicable): Each patient will have an extension to their standard, radiotherapy planning MRI scan taken for regular clinical care. This scan will last at maximum 60 minutes.

Main study parameters/endpoints: Equal prediction of pattern of failure (locations of tumour recurrence) based on the physiological CTV compared to the standard CTV used for radiotherapy planning, with the physiological CTV being smaller in volume.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The patients the burden of prolonged scan time (+ 30 minutes, scan will last 60 mins in total) during their standard RT planning scan. The remainder of their clinical care will not be altered: RT will be given to these patients based on standard CTVs. Follow-up will follow the clinical protocol . There will be no personal benefit for the patients in this research project.

Conditions
Glioblastoma
Being tested
Extended MRI
Keywords
Glioblastoma, Precision radiotherapy, Advanced MRI
Medical subject headings
Glioblastoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Extended MRIDiagnostic test

    Extension of the brain tumor MRI-protocol

Study groups in NCT05970757
Study groupRoleWhat they receive
Extended MRI groupOtherThe MRI-scan time is extended with 15-20 minutes.
Receives: Diagnostic Test: Extended MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Volume and location analysis of physiological and standard CTV

    Volume and location analysis (Dice correlation coeffcient) will be done to compare the physiological CTVs to standard CTVs generated pre-radiotherapy, where it is hypothesized that the physiological CTVs will be overall smaller in volume and better match microinvasion of the tumour than the standard CTV.

    Measured: Time frame is directly after the extended MRI-acquisition

Secondary outcomes (1)
  1. Pattern-of-failure analysis of the physiological and standard CTV

    In the standard follow-up of patients, repeat MRI scans are made every 3 to 4 months. RANO criteria will be used to do response assessment and to determine if and when tumour recurrence is occurring. Pattern-of-failure analysis will then be done with the physiological CTV and the standard CTV, where the percentage of overlap of the recurrence volume with the physiological and standard CTV will be assessed. The hypothesis is that the percentage overlap will not be worse for the physiological CTV compared to the standard CTV, whilst the physiological CTV will be smaller in volume than the standard CTV.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2023
  2. Study start14 Jul 2022
  3. Primary completion15 Dec 2023
  4. Study completion15 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05970757
Sponsor's protocol ID
NL80747.078.22
Acronym
PhysMRRT
Status last verified
Aug 2025
First submitted
24 Jul 2023
Last updated
11 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Not available yet

Publications

  • Tang PLY, Romero AM, Nout RA, van Rij C, Slagter C, Swaak-Kragten AT, Smits M, Warnert EAH. Amide proton transfer-weighted CEST MRI for radiotherapy target delineation of glioblastoma: a prospective pilot study. Eur Radiol Exp. 2024 Oct 30;8(1):123. doi: 10.1186/s41747-024-00523-4.

    PubMed 39477835

Questions about this trial

What is this clinical trial studying?

A study testing Extended MRI in people with Glioblastoma, run by Erasmus Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Volume and location analysis of physiological and standard CTV (time frame: Time frame is directly after the extended MRI-acquisition). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05970757, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in